protein

Influenza A Virus H3N2 Brisbane 10/07

MBS143232

0.01 mg

140 USD

Native Protein

Influenza A Virus H3N2 Brisbane 10/07

Influenza A Virus H3N2 Brisbane 10/07

H3N2 Brisbane; H3N2 Influenza-A Virus Brisbane 10/07; Brisbane 10/07

Greater than 90.0% as determined byAnalysis by SDS-PAGE.

The H3N2 A/Brisbane/10/07 solution contains STE, 0.1 % sodium azide (NaN3) and 0.005 % thimerosal. Sterile Filtered whitish (milky) solution.

Immunological Activity: Tested with anti-influenza A monoclonal antibodies in ELISA.Serological studies of influenza A virus, immunogen for antibody production.

Inactivation: Thimerosal and beta propiolactone treatmentThis product has been treated in a manner consistent with methods of inactivation. Generally accepted good laboratory practices appropriate to microbiological/viral safe handling practices and techniques are required at work.

VIRAL ANTIGENS- INFLUENZA VIRUS; Viral Antigens; Influenza

Description: Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza A virus, strain A/Brisbane/10/07. The Influenza Virus was purified by Ultracentrifugation with 10-40 % sucrose gradient. Introduction: H3N2 is a subtype of the influenza A virus. Its name derives from the forms of the two kinds of proteinson the surface of its coat, hemagglutinin(H) and neuraminidase(N). H3N2 exchanges genes for internal proteins with other influenza subtypes. H3N2 has tended to dominate in prevalence over H1N1, H1N2, and influenza B. H3N2 strain descended from H2N2by antigenic shift, in which genes from multiple subtypes re-assorted to form a new virus. Both the H2N2and H3N2 strains contained genesfrom avian influenzaviruses.

0.01 mg

140 USD

0.05 mg

205

1 mg

1980